Publication Date: 1/6/2010
Victoza® (liraglutide) is the second drug in a new class of injectible diabetes medications, called GLP-1 receptor agonists. It was approved for use in Europe in 2009, and was approved in the United States in January 2010.
liraglutide
- Brand name: Victoza®
- Class: Glucagon-Like Peptide-1 (GLP-1) receptor agonist
- For: Type 2 diabetes
- Route of Administration: once-daily injection
- Action: mimicks GLP-1, allowing secretion of insulin by beta cells. Also delays gastric emptying, and suppresses meal-related glucagon secretion.
- Manufacturer: Novo Nordisk
- Status: Approved in Europe July 3 2009; approved by the FDA January 25, 2010.
- Source: Press releases from manufacturer, Novo Nordisk's Victoza® (liraglutide) receives marketing authorisation in Europe (3 July 2009), Novo Nordisk receives US approval for Victoza? (liraglutide) for the treatment of type 2 diabetes (26 January 2010)
- Other drugs in the same class: Byetta (exenatide) (approved in US and Europe).
Also see
liraglutide At Wikipedia.
